Cellavision: Q4’22, Challenges continues. - Redeye

Redeye’s first view on the Q4 report this morning. Cellavision clearly continues to see challenges evident in the weaker-than-expected report this morning. The organic growth was negative 17% in the quarter, whereas the Americas and APAC were particularly weak this quarter. The challenges seen in Q3 seem to linger longer than expected.

Länk till analysen i sin helhet: https://www.redeye.se/research/874329/cellavision-q422-challenges-continues?utm_source=finwire&utm_medium=RSS